0001104659-19-065857.txt : 20191120 0001104659-19-065857.hdr.sgml : 20191120 20191120161548 ACCESSION NUMBER: 0001104659-19-065857 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191119 FILED AS OF DATE: 20191120 DATE AS OF CHANGE: 20191120 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Aghazadeh Behzad CENTRAL INDEX KEY: 0001701815 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-12104 FILM NUMBER: 191234412 MAIL ADDRESS: STREET 1: C/O AVORO CAPITAL ADVISORS LLC STREET 2: 110 GREENE STREET, SUITE 800 CITY: NEW YORK STATE: NY ZIP: 10012 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Avoro Capital Advisors LLC CENTRAL INDEX KEY: 0001633313 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-12104 FILM NUMBER: 191234413 BUSINESS ADDRESS: STREET 1: 110 GREENE STREET STREET 2: SUITE 800 CITY: NEW YORK STATE: NY ZIP: 10012 BUSINESS PHONE: 212-937-4975 MAIL ADDRESS: STREET 1: 110 GREENE STREET STREET 2: SUITE 800 CITY: NEW YORK STATE: NY ZIP: 10012 FORMER NAME: FORMER CONFORMED NAME: venBio Select Advisor LLC DATE OF NAME CHANGE: 20150210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNOMEDICS INC CENTRAL INDEX KEY: 0000722830 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 611009366 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 AMERICAN RD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 BUSINESS PHONE: 9736058200 MAIL ADDRESS: STREET 1: 300 AMERICAN ROAD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 4 1 a4.xml 4 X0306 4 2019-11-19 0 0000722830 IMMUNOMEDICS INC IMMU 0001701815 Aghazadeh Behzad C/O AVORO CAPITAL ADVISORS LLC 110 GREENE STREET, SUITE 800 NEW YORK NY 10012 1 0 1 1 See Remarks 0001633313 Avoro Capital Advisors LLC C/O AVORO CAPITAL ADVISORS LLC 110 GREENE STREET, SUITE 800 NEW YORK NY 10012 1 0 1 1 See Remarks Stock Option (right to buy) 18.74 2019-11-19 4 A 0 150000 0 A 2026-11-19 Common Stock, par value $0.01 per share 150000 150000 D Dr. Aghazadeh was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan. 50,000 of the stock options vest upon the U.S. Food and Drug Administration's ("FDA") acceptance of the resubmission of the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act (the "BLA"), and 100,000 of the stock options vest upon the Issuer's receipt of approval from the FDA for the BLA. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors LLC (formerly venBio Select Advisor LLC), a Delaware limited liability company (the "Investment Manager"). The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. The Investment Manager may be deemed a director by deputization of Immunomedics, Inc. (the "Issuer") by virtue of the fact that Dr. Aghazadeh currently serves on the board of directors of the Issuer. /s/ Behzad Aghazadeh 2019-11-19 Avoro Capital Advisors LLC, by: /s/ Behzad Aghazadeh, authorized signatory 2019-11-19